Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$332.60K$332.60Kderived+119.8% vs Q4 2020 Net Income-$1.84M-$1.84MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,874,024N/M Operating Cash Flowderived-$1,458,699N/M Margins · derivedOperating margin-563.4%+242.7 pt vs Q4 2020
Net margin-553.7%+239.3 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 22, 2022 · 81 d after period end